.png){kind=icon}
.png){kind=icon}
Return
Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia
.png){kind=icon}
PRE
AI
DOI：10.1176/ajp.156.1.145.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Objective: The focus of this study was the systematic evaluation of the clinical effects of glycine as an adjunct to the atypical antipsychotic clozapine in the treatment of schizophrenia. Method: In a double-blind, placebo-controlled study, 19 patients with chronic, treatment-resistant schizophrenia who were maintained on optimal doses of clozapine (400-1200 mg/day) were administered either 30 g/day of glycine (N=9) or placebo (N=10) for 12 weeks. Clinical evaluations with the Brief Psychiatric Rating Scale, the Scale for the Assessment of Negative Symptoms, and the Simpson-Angus movement scale were completed biweekly. Results: The use of glycine as an adjunct to clozapine was not effective in decreasing positive or negative symptoms. In contrast, the patients treated with clozapine without glycine had a 35% reduction in positive symptoms. Conclusions: These preliminary data suggest that glycine may interfere with the antipsychotic efficacy of atypical neuroleptics such as clozapine.
Keywords:
CONVENTIONAL NEUROLEPTIC TREATMENT
ADJUVANT THERAPY
D-CYCLOSERINE
NEGATIVE SYMPTOMS
OPEN-LABEL
TRIAL
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
14.7
Papers:
1.2W
Citations:
3.8W
Organization
No organization information available